Meeting abstracts
AAD 2026
American Academy of Dermatology · Denver, 27–31 March 2026
1,877 abstracts, published in JAAD on 6 July 2026. Their text is on the JAAD website.
- 71239
- 72223
- 72321
Cutaneous immune-related adverse events in people living with HIV receiving immune checkpoint inhibitors for advanced malignancy
Corey S, Thompson BB, … senior author Chen ST
- 72505
Oral Bexarotene as a First-Line Systemic Therapy for Cutaneous T-Cell Lymphoma
Hill M, Larson E, Cooper K
- 72811
Navigating Immune Checkpoint Inhibitor Therapy in Patients with Dermatomyositis
Martin M, Ristianto ZA, … senior author Femia A
- 73764
- 73958
Severe Presentations of Cutaneous Lupus in Patients on Immune Checkpoint Inhibitors (ICIs)
Schwierking S, Brokamp G, … senior author Dulmage B
- 74151
Characterizing immune checkpoint inhibitor-associated vitiligo: a single-institution cohort
Lu K, Enriquez K, Dobry A
- 74159
Pembrolizumab in Heavily Pretreated Cutaneous T-Cell Lymphoma: Outcomes from a Single-Center
Khoshniyati S, Sterling C, Rozati S
- 74215
A Phase 1b Randomized, Double-Blind Multiple-Ascending Dose Study of NAV-240, an anti-OX40L/TNF-alpha Bispecific Antibody, in Healthy Volunteers
Daryani N, McClintock D, Pupim L, et al.
- 74490
Preclinical Characterization of NAV-242, a half-life extended bispecific antibody against TNF-alpha and OX40L
Daryani N, Mack T, … senior author Grebe K
- 74538
Adoption of Immunotherapy has Improved Merkel Cell Carcinoma Survival
Chefitz G, Fragano A, … senior author Brownell I
- 74674
Distinct Timing and Spectrum of Skin Reactions to PD-1 Inhibitors Across Cancer Types: A Comprehensive Systematic Review
Rahmanzai M, Antonson M, Ogah O
- 74709
- 74713
Evaluating Disparities in Counseling and Resources for Chemotherapy-Induced Hair Loss: Quantitative Analysis of a Survey-Based Approach
Kaufman L, Valentic L, … senior author Dulmage B
- 74824
Immune Checkpoint Inhibitor-Eczema: Results from a Multi-Institutional Cohort Study
Hill J, Adams P, … senior author Kaffenberger B
- 75128
Engineering and Development of a Novel Bispecific Antibody Targeting IL13 and IL31
Huang J, Ran H, … senior author Zhu Z
- 75131
Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders
Zhang X, Huan L, … senior author Zhu Z
- 75134
AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody
Zhang Y, Ran H, … senior author Zhu Z
- 75298
Immune checkpoint inhibitor-related psoriatic arthritis: systemic steroid overuse and recommendations for targeted therapeutic alternatives
Hanrahan G, Said J, … senior author LeBoeuf N
- 75365
NEOADJUVANT CEMIPLIMAB TO FACILITATE MOHS SURGERY TUMOR EXTIRPATION AND REDUCE SURGICAL MORBIDITY
Cortes M, Santana J, Strasswimmer J
- 75519
Germline Pathogenic Variants Confer Increased Susceptibility to Immune-Related Adverse Events in Patients With Melanoma Treated with Immune Checkpoint Inhibitors
Shen A, Arbesman M, … senior author Kennedy L
- 75623
Evaluating Disparities in Counseling and Resources for Chemotherapy-Induced Hair Loss: A Qualitative Survey-Based Approach
Khuhro A, Kaufman L, … senior author Dulmage B
- 75723
- 75999
- 76027
Presentation of Toxic Erythema of Chemotherapy in Patients with Skin of Color
Mittal S, Guhan S, … senior author Nguyen CV
- 76107
- 76120
- 76260
Trichoscopic Patterns for Chemotherapy-Induced Alopecia in Patients Receiving Scalp Cooling Treatment
Rachofsky C, Alicea D, … senior author McLellan B
- 76399
Cutaneous Adverse Events from Immune Checkpoint Inhibitors: A Review of Clinical Patterns and Management Strategies
Wahab G, Wojtara M, … senior author Cooper A
- 76500
A Review of Hedgehog Pathway Inhibitors in Combination Therapy for Basal Cell Carcinoma
Jeon H, Berman S, Zeitouni N
- 76551
Targeted Therapies and PARPi Therapy Response Following ICI Therapy Failure in Advanced Melanoma
Morecroft R, Nassief G, … senior author Ansstas G
- 76646
Cutaneous Adverse Reactions and Antibody-Drug Conjugates: A FAERS 2019-2025 Disproportionality Analysis
Cassidy C, Austin E, Feig JL
- 77155
From Survival to Side Effects: Retrospective Analysis of Adverse Events in Checkpoint Inhibitor Therapy for Melanoma Using the FAERS Database
Guermazi D, Liu M, … senior author Saliba E
- 77236
Vitiligo after anti–PD-1 therapy in melanoma: landmarked, propensity-matched survival analyses from a real-world EHR network
Mojena M, Kollings J, Sunshine J
- 77454
Risk of Cutaneous Squamous Cell Carcinoma Development Following PD-1 Inhibitor Therapy for Melanoma
Nusrat F, Lauck K, … senior author Lawrence N
That's every abstract.